CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. (Q53721452)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. |
scientific article |
Statements
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. (English)
1 reference
1 reference
Pierre Clavelou
1 reference
BĂ©atrice Pignolet
1 reference
Florence Bucciarelli
1 reference
Damien Biotti
1 reference
Delphine Averseng-Peaureaux
1 reference
Olivier Outteryck
1 reference
Jean-Claude Ongagna
1 reference
Jérôme de Sèze
1 reference
Bruno Brochet
1 reference
Jean-Christophe Ouallet
1 reference
Marc Debouverie
1 reference
Sophie Pittion
1 reference
Gilles Defer
1 reference
Nathalie Derache
1 reference
Patrick Hautecoeur
1 reference
Ayman Tourbah
1 reference
Pierre Labauge
1 reference
Giovanni Castelnovo
1 reference
Eric Berger
1 reference
Jean Pelletier
1 reference
Audrey Rico
1 reference
Hélène Zéphir
1 reference
David Laplaud
1 reference
Sandrine Wiertlewski
1 reference
William Camu
1 reference
Eric Thouvenot
1 reference
Olivier Casez
1 reference
Thibault Moreau
1 reference
Agnès Fromont
1 reference
Sandra Vukusic
1 reference
Caroline Papeix
1 reference
Patrick Vermersch
1 reference
Manuel Comabella
1 reference
Christine Lebrun-Frenay
1 reference
David Brassat
1 reference
BIONAT, SFSEP, and BEST-MS networks
1 reference
4 November 2016
1 reference
1 reference
87
1 reference
23
1 reference
2491-2494
1 reference
Identifiers
1 reference